{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:57:55Z","timestamp":1790398675293,"version":"4.1.0"},"reference-count":21,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"accepted":{"date-parts":[[1997,1,23]]},"published-print":{"date-parts":[[1997,8,1]]},"abstract":"<jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    \u2014The use of corticosteroids in active Crohn\u2019s disease often becomes limited by side effects. Budesonide is a potent corticosteroid with low systemic bioavailability due to an extensive first pass liver metabolism.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Aims<\/jats:italic>\n                    \u2014To compare the efficacy and safety of two dosage regimens of budesonide and prednisolone in patients with active Crohn\u2019s disease affecting the ileum and\/or the ascending colon.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Patients and methods<\/jats:italic>\n                    \u2014One hundred and seventy eight patients were randomised to receive budesonide controlled ileal release (CIR) capsules 9 mg once daily or 4.5 mg twice daily, or prednisolone tablets 40 mg once daily. The treatment period was 12 weeks. The primary efficacy variable was clinical remission, defined as a Crohn\u2019s Disease Activity Index (CDAI) of 150 or less.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    \u2014After eight weeks of treatment, remission occurred in 60% of patients receiving budesonide once daily or prednisolone and in 42% of those receiving budesonide twice daily (p=0.062). The presence of glucocorticoid associated side effects was similar in all groups; however, moon face was more common in the prednisolone group (p=0.0005). The highest frequency of impaired adrenal function, as measured by a short ACTH test, was found in the prednisolone group (p=0.0023).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions<\/jats:italic>\n                    \u2014Budesonide CIR, administered at 9 mg once daily or 4.5 mg twice daily, is comparable to prednisolone in inducing remission in active Crohn\u2019s disease. The single dose administration is as promptly effective as prednisolone and represents a simpler and safer therapeutic approach, with a considerable reduction in side effects.\n                  <\/jats:p>","DOI":"10.1136\/gut.41.2.209","type":"journal-article","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T12:46:12Z","timestamp":1277901972000},"page":"209-214","source":"Crossref","is-referenced-by-count":256,"title":["Oral budesonide is as effective as oral prednisolone in active Crohn\u2019s disease"],"prefix":"10.1136","volume":"41","author":[{"given":"M","family":"Campieri","sequence":"first","affiliation":[{"name":"aMedical and Gastroenterological Clinic, University of Bologna, Italy, \n\nbDepartment of Medicine, University of Edinburgh, Edinburgh, \n\ncDivision of Molecular Medicine, John Curtin School of Medical Research, Canberra, Australia, \n\ndAstra Draco AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ferguson","sequence":"additional","affiliation":[{"name":"aMedical and Gastroenterological Clinic, University of Bologna, Italy, \n\nbDepartment of Medicine, University of Edinburgh, Edinburgh, \n\ncDivision of Molecular Medicine, John Curtin School of Medical Research, Canberra, Australia, \n\ndAstra Draco AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Doe","sequence":"additional","affiliation":[{"name":"aMedical and Gastroenterological Clinic, University of Bologna, Italy, \n\nbDepartment of Medicine, University of Edinburgh, Edinburgh, \n\ncDivision of Molecular Medicine, John Curtin School of Medical Research, Canberra, Australia, \n\ndAstra Draco AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Persson","sequence":"additional","affiliation":[{"name":"aMedical and Gastroenterological Clinic, University of Bologna, Italy, \n\nbDepartment of Medicine, University of Edinburgh, Edinburgh, \n\ncDivision of Molecular Medicine, John Curtin School of Medical Research, Canberra, Australia, \n\ndAstra Draco AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L-G","family":"Nilsson","sequence":"additional","affiliation":[{"name":"aMedical and Gastroenterological Clinic, University of Bologna, Italy, \n\nbDepartment of Medicine, University of Edinburgh, Edinburgh, \n\ncDivision of Molecular Medicine, John Curtin School of Medical Research, Canberra, Australia, \n\ndAstra Draco AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Global Budesonide Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[1997,8,1]]},"reference":[{"key":"2025120617582826000_41.2.209.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110033251406"},{"key":"2025120617582826000_41.2.209.2","first-page":"42","article-title":"Medical management of Crohn\u2019s disease.","volume":"37","author":"Meyers","year":"1990","journal-title":"Hepatogastroenterology"},{"key":"2025120617582826000_41.2.209.3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn\u2019s Disease Study: results of drug treatment.","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"2025120617582826000_41.2.209.4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1155\/1990\/708916","article-title":"Overview of newer glucocorticoid preparations for inflammatory bowel disease.","volume":"4","author":"Brattsand","year":"1990","journal-title":"Can J Gastroenterol"},{"key":"2025120617582826000_41.2.209.5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199244030-00007","article-title":"Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis.","volume":"44","author":"Brogden","year":"1992","journal-title":"Drugs"},{"key":"2025120617582826000_41.2.209.6","doi-asserted-by":"publisher","DOI":"10.3109\/00365529108998618"},{"key":"2025120617582826000_41.2.209.7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2036.1994.tb00340.x","article-title":"Budesonide versus prednisolone retention enema in active distal ulcerative colitis.","volume":"8","author":"L\u00f6fberg","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120617582826000_41.2.209.8","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199402000-00007"},{"key":"2025120617582826000_41.2.209.9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2036.1994.tb00335.x","article-title":"Budesonide enema is as effective as hydrocortisone foam in proctitis.","volume":"8","author":"Tarpila","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120617582826000_41.2.209.10","first-page":"A695","article-title":"Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules.","volume":"104","author":"Edsb\u00e4cker","year":"1993","journal-title":"Gastroenterology"},{"key":"2025120617582826000_41.2.209.11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2036.1993.tb00141.x","article-title":"Oral budesonide in active Crohn\u2032s disease.","volume":"7","author":"L\u00f6fberg","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120617582826000_41.2.209.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311303"},{"key":"2025120617582826000_41.2.209.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311304"},{"key":"2025120617582826000_41.2.209.14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study.","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"2025120617582826000_41.2.209.15","unstructured":"\u00d6gren L, J\u00f6nsson P. Determination of cortisol in human plasma by solid phase extraction and coupled column liquid chromatography. Astra Draco Report 850-RD-0323, 1994. ."},{"key":"2025120617582826000_41.2.209.16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn\u2019s Disease Study (ECCDS): results of drug treatment.","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"2025120617582826000_41.2.209.17","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199106030-00005"},{"key":"2025120617582826000_41.2.209.18","doi-asserted-by":"publisher","DOI":"10.3109\/02770908809071368"},{"key":"2025120617582826000_41.2.209.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-3-304"},{"key":"2025120617582826000_41.2.209.20","doi-asserted-by":"crossref","first-page":"A814","DOI":"10.1016\/0016-5085(95)27565-7","article-title":"Budesonide controlled ileal release (CIR) capsules affect plasma cortisol less than prednisolone.","volume":"108","author":"Edsb\u00e4cker","year":"1995","journal-title":"Gastroenterology"},{"key":"2025120617582826000_41.2.209.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311311"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gut.41.2.209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T01:58:34Z","timestamp":1765072714000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gut.41.2.209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,8,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[1997,8,1]]},"published-print":{"date-parts":[[1997,8,1]]}},"alternative-id":["10.1136\/gut.41.2.209"],"URL":"https:\/\/doi.org\/10.1136\/gut.41.2.209","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,8,1]]}}}